On January 9, Merck China announced the approval of its two-dose regimen of the nine-valent HPV vaccine for females aged 9 to 14 by the China National Medical Products Administration, a move perceived as a "price reduction" by industry observers.
April 4, 2024
By Cathy Yin-Garton, Grace Hsing